abemaciclib
E1556480
UNEXPLORED
Abemaciclib is an oral anticancer drug that selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), used primarily in the treatment of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
All labels observed (1)
| Label | Occurrences |
|---|---|
| abemaciclib canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T22796788 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: abemaciclib Context triple: [CDK6, isDrugTargetOf, abemaciclib]
-
A.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
B.
dalpiciclib
Dalpiciclib is an investigational small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) being developed primarily for the treatment of hormone receptor–positive breast cancer.
-
C.
trilaciclib
Trilaciclib is an intravenous cyclin-dependent kinase 4/6 inhibitor used to protect bone marrow from chemotherapy-induced damage in patients with certain cancers.
-
D.
lapatinib
Lapatinib is an oral small-molecule tyrosine kinase inhibitor used primarily to treat HER2-positive breast cancer.
-
E.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: abemaciclib Target entity description: Abemaciclib is an oral anticancer drug that selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), used primarily in the treatment of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
A.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
B.
dalpiciclib
Dalpiciclib is an investigational small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) being developed primarily for the treatment of hormone receptor–positive breast cancer.
-
C.
trilaciclib
Trilaciclib is an intravenous cyclin-dependent kinase 4/6 inhibitor used to protect bone marrow from chemotherapy-induced damage in patients with certain cancers.
-
D.
lapatinib
Lapatinib is an oral small-molecule tyrosine kinase inhibitor used primarily to treat HER2-positive breast cancer.
-
E.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.